Celularity Company

Celularity and Sorrento Therapeutics are working in CYNK-001, an allogeneic, off-the-shelf Natural Killer (NK) cell therapy developed from placental hematopoietic stem cells; also being developed in multiple myeloma, acute myeloid leukemia, glioblastoma multiforme and various blood and solid tumors.

Celularity on April 2 won FDA clearance for its IND of CYNK-001 in adults with COVID-19, allowing the company to begin a Phase I/II trial of up to 86 patients. The IND followed high-profile efforts to promote CYNK-001, including a March 13 op-ed commentary by CEO Robert J. Hariri, MD, PhD, in The Wall Street Journal, and public support by President Donald Trump’s personal lawyer Rudy Giuliani, who invited Hariri onto his “Common Sense podcast: “Trials need to be EXPEDITED,” he tweeted on March 27.

Investors

Headquarters: United States
Funding Status: N/A
Employee Number: N/A
Investment Stage: N/A
Number Of Exists: N/A
Technology: COVID
Investor Type: N/A
Founded Date: N/A
Industry: Treatments
N/A
Register and Claim Ownership